Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVT DURATION
NCT07246005Phase 2Not yet recruiting
- Sponsor
- Queen Mary University of London
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apixaban, rivaroxaban, warfarin in left ventricular thrombus (LVT), sponsored by Queen Mary University of London. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
apixabanrivaroxabanwarfarin
03
Conditions
left ventricular thrombus (LVT)
Beyond the preview
Go deeper on NCT07246005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07246005.